Atreca Inc
General ticker "BCEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.6M
Atreca Inc does not follow the US Stock Market performance with the rate: -22.0%.
Estimated limits based on current volatility of 3.4%: low 0.09$, high 0.10$
Factors to consider:
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term predictions were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 predicted range: [0.73$, 2.13$]
- 2023-12-31 to 2024-12-30 predicted range: [0.83$, 2.22$]
Financial Metrics affecting the BCEL estimates:
- Negative: Non-GAAP EPS of -2.52 <= 0.08
- Negative: Operating Cash Flow per share of -2.09 <= 0.20
- Negative: Operating Income to Revenue ratio of -0.99 <= 0.01
- Negative: negative Net Income
- Negative: Industry Operating Cash Flow per share (median) of -1.75 <= 0.29
Short-term BCEL quotes
Long-term BCEL plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $1.35MM | $0.85MM | $0.77MM |
| Operating Expenses | $87.66MM | $114.65MM | $104.56MM |
| Operating Income | $-86.31MM | $-113.80MM | $-103.79MM |
| Non-Operating Income | $-0.03MM | $4.47MM | $6.63MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $62.05MM | $78.35MM | $66.83MM |
| Income(Loss) | $-86.33MM | $-109.33MM | $-97.16MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Profit(Loss) | $-86.33MM | $-109.33MM | $-97.16MM |
| Stockholders Equity | $242.06MM | $154.93MM | $78.41MM |
| Assets | $272.06MM | $200.06MM | $155.03MM |
| Operating Cash Flow | $-66.67MM | $-60.92MM | $-80.72MM |
| Investing Cash Flow | $-159.00MM | $89.24MM | $12.55MM |
| Financing Cash Flow | $128.87MM | $5.45MM | $3.90MM |
| Earnings Per Share* | $-2.70 | $-2.95 | $-2.35 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.